U.S. Markets open in 6 hrs 25 mins

BioCryst Pharmaceuticals, Inc. (BCRX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.24-0.24 (-4.38%)
At close: 4:00PM EDT
People also watch
NVAXHEBVICLARRYACAD
  • BCRX is getting hammered lately, ouch!
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states:
    • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence late 2017
    • Sales and or licensing agreement/s could be very significant and fast
    • Company is now commercializing several other disruptive products in large markets

    http://www.clyramedical.com

    https://www.sec.gov/Archives/edgar/data/880242/000143774917009469/blgo20170331_10q.htm

  • someone decided to buy some shares today, why? did something leak (rhetorical question)?
  • first morning when down huge (10% or more) in pre market is the time to buy buy buy hand over fist!
  • So just in case I do not understand too well, company beats earnings (loss) and beats revenue projections and the PPS takes a hit of 10% or more, what am I missing?
  • If my crystal ball were working , would have sold at 9 and bought back. One would figure with more countries selling their products it would have to help earnings. Keep holding......
  • Who is unloading so much BCRX??? day after day she falls!!! now about 40% of it's high about a month ago.
  • NIAID BAA 2017-1, Amendment 2 , April 28 seeking Broad Spectrum Antiviral

    Page 29 of the solicitation, Research Area 004, Section 2. Antiviral Broad-spectrum Therapeutics, states that a candidate antiviral therapeutic product must meet all of the criteria identified. Thus, an antiviral broad spectrum therapeutic that displays activity against Arenaviruses (part of the Category A viral pathogens under the NIAID Priority Pathogens List), must also display activity against infection caused by two or more viruses from the families identified in Section 2.b. to be considered responsive.
  • short covering before earnings?
  • Peramivir has been approved in China years ago. I wonder why the BioCryst never mentions it?
  • bcrx=POS
  • BCRX has temporarily lost its mojo; have the baker bros. been unloading or something else? anyone know? Will BCRX rebound to the $9 level anytime in the next 3 months?
  • What the hay happened to BCRX today? Longs are smarting.... Are the Baker bros. selling already?
  • AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000%+ POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $50.6 Million(cash runway into the first quarter of 2019.)
    Price:$3.70

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Fools talk because they have to say something. http://dataunion.tistory.com/1287

    [2016-MAY] BioCryst Pharmaceuticals NASDAQ : BCRX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.6 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • how high today? Needham conference tomorrow
  • Downside risk pretty much eliminated now that BCRX has seen EPS growth % next Year reached the lower limits of 2.90%. Ive been struggling with this stock lately. Some of my other trades have been from aawesomestocks which are working out pretty well.
  • you guys need to redo your evaluation stock going to $10.00
  • Is it time to make a move on BCRX? It certainly looks like it based on a analyst mean target price of 7.78. goog allerted a new stock just now. going to check it out.
  • On our way to $8.00 again!!!!